KALA

KALA BIO, Inc.

8.01 USD

Last updated Nov 30, 08:31 UTC

Yesterday HIGH

$6.2

Yesterday LOW

$5.6

52w HIGH

$56.72

52w LOW

$3.54

EPS

-3.41

PE

-2.35

Next Earnings

Mar 1, 2024

Overview News Government Trades

KALA BIO, Inc. stock is up 16.09% since 30 days ago. The next earnings date is Mar 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 November’s closed higher than October. 100% of analysts rate it a buy.

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

kalarx.com

richadhand@benzinga.com

Wed Apr 12, 2023

HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Raises Price Target to $22

HC Wainwright & Co. analyst Yi Chen maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and raises the price target from $20 to $22.
Steve Krause

Wed Apr 12, 2023

Kala Pharmaceuticals Receives FDA Fast Track Designation For KPI-012 For Persistent Corneal Epithelial Defect
Christopher Sappo

Tue Apr 4, 2023

Short Interest Sector Focus: Healthcare Sector

As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector stands at 3.06%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.
Chris Katje

Mon Apr 3, 2023

5 Short Squeeze Stocks To Watch: Unicycle Therapeutics, Getty Images And More

Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Chris Katje

Mon Mar 27, 2023

10 Short Squeeze Candidates: Unicycle Therapeutics, Compass Pathways, Virgin Orbit Among Those To Watch

Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Vandana Singh

Mon Mar 27, 2023

Kala Pharma Reveals Safety Data From Stem Cell Therapy Trial For Corneal Defect Impacting Around 240K People In Developed Nations
Benzinga Newsdesk

Mon Mar 27, 2023

HC Wainwright & Co. Reiterates Buy on Kala Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and maintains $20 price target.
Benzinga Newsdesk

Mon Mar 27, 2023

Kala Pharmaceuticals Reports Safety Update From Cohort 1 Of CHASE Phase 2b Clinical Trial Evaluating KPI-012 In Patients With PCED

The first cohort enrolled two patients, treated with a high dose of KPI-012 (3 U/mL) four times per day (QID). Both patients successfully completed at least one week of dosing with no safety issues observed. The trial
Chris Katje

Mon Mar 20, 2023

10 Short Squeeze Candidates: PaxMedica, Blue Apron, MicroStrategy And More

Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Chris Katje

Mon Mar 13, 2023

5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.